C19orf57

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, C19orf57 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C19orf57 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher C19orf57 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C19orf57 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THCA and UCEC are the cancer types where C19orf57 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
THCAOSMedianAll0.3230.955<.0018view →
UCECDFSMedianII,III,IV0.9150.305.0228view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C19orf57–THCA (OS)

Kaplan–Meier survival curve for C19orf57 mutant vs wild-type samples in THCA.

Open the THCA breakdown →

Exploration